Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2004;35:1995-1998
Published online before print July 1, 2004, doi: 10.1161/01.STR.0000135228.20619.ad
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/8/1995    most recent
01.STR.0000135228.20619.adv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hankey, G. J.
Right arrow Articles by Eikelboom, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hankey, G. J.
Right arrow Articles by Eikelboom, J. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*FOLIC ACID
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Other Treatment
Right arrow Other Stroke

(Stroke. 2004;35:1995.)
© 2004 American Heart Association, Inc.


Emerging Therapies

Folic Acid–Based Multivitamin Therapy to Prevent Stroke

The Jury Is Still Out

Graeme J. Hankey, MD, FRCP, FRACP John W. Eikelboom, MBBS, MSc, FRACP, FRCPA

From the Stroke Unit (G.J.H.) and the Department of Haematology (J.W.E.), Royal Perth Hospital, Perth, Australia; and the School of Medicine and Pharmacology (G.J.H., J.W.E.), University of Western Australia, Crawley, Australia.

Correspondence to Dr Graeme J. Hankey, Clinical Professor, VITATOPS Trial Office, Stroke Unit, Department of Neurology, Royal Perth Hospital, 197 Wellington St, Perth, Australia 6001. E-mail gjhankey@cyllene.uwa.edu.au


Key Words: vitamin B complex • stroke prevention • folic acid • homocysteine • clinical trials


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

There is a large body of observational and laboratory evidence suggesting but not proving that increasing plasma concentrations of total homocysteine (tHcy) is a causal risk factor for atherothromboembolic ischemic stroke and other vascular events.1–9

Recent publication of the results of the landmark Vitamins in Stroke Prevention (VISP) Trial is the first evidence from a large randomized controlled trial (RCT) of the effect of lowering tHcy via folic acid–based multiple B vitamin supplementation on the incidence of "hard" clinical events, such as recurrent stroke, in patients with recent ischemic stroke.10,11 In contrast to what was expected from the epidemiological evidence, the VISP Trial did not identify a significant treatment effect of lowering tHcy by vitamin therapy on recurrent stroke, coronary events, or death, despite confirming a consistent and graded association between baseline tHcy and vascular risk (particularly the probability of stroke over time).11 Recruiting primarily from North America, VISP enrolled 3680 recent (3 to 120 days) survivors of nondisabling, noncardiogenic, ischemic stroke with baseline tHcy above the 25th percentile of the North American stroke population into a double-blind, randomized comparison of high versus low doses of a combination of 12 different vitamins, including folic acid, vitamin B12, vitamin B6, and riboflavin, which are cofactors for enzymes responsible for metabolizing homocysteine.11 After 2 years of follow-up, there was no significant difference in the cumulative incidence of the primary outcome event of recurrent cerebral infarction: 8.4% of 1814 patients who were allocated to high-dose multivitamins [including 2.5 mg of folic . . . [Full Text of this Article]